Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma

Expert opinion

Axel Hauschild, Helen Gogas, Ahmad Tarhini, Mark R. Middleton, Alessandro Testori, Brigitte Dréno, John M. Kirkwood

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Interferon-α-2b (IFNα2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from this agent. A review of the literature demonstrated little recent attention to supportive care in the management of IFN toxicities. An international group of experts with extensive personal experience in the use of IFNs worked together to develop practical guidelines for the use of IFNs. Practical recommendations were developed for patient education on the use of IFN; initial patient assessment and monitoring, including contraindications to the use of IFN, monitoring and managing adverse events, and IFN dose modification and discontinuation; IFN injection procedures; treatment of elderly patients; and use during pregnancy and nursing. Successful adjuvant therapy of melanoma with high-dose IFN requires close compliance with the treatment regimen. Recommendations for the recognition and management of adverse events are designed to enable more patients to complete the full planned course of treatment.

Original languageEnglish
Pages (from-to)982-994
Number of pages13
JournalCancer
Volume112
Issue number5
DOIs
Publication statusPublished - Mar 1 2008

Fingerprint

Expert Testimony
Interferons
Melanoma
Guidelines
Therapeutics
Physiologic Monitoring
Patient Education
Nursing
Recurrence
Pregnancy
Injections

Keywords

  • Adjuvant therapy
  • Adverse events
  • Interferon
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hauschild, A., Gogas, H., Tarhini, A., Middleton, M. R., Testori, A., Dréno, B., & Kirkwood, J. M. (2008). Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion. Cancer, 112(5), 982-994. https://doi.org/10.1002/cncr.23251

Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma : Expert opinion. / Hauschild, Axel; Gogas, Helen; Tarhini, Ahmad; Middleton, Mark R.; Testori, Alessandro; Dréno, Brigitte; Kirkwood, John M.

In: Cancer, Vol. 112, No. 5, 01.03.2008, p. 982-994.

Research output: Contribution to journalArticle

Hauschild, A, Gogas, H, Tarhini, A, Middleton, MR, Testori, A, Dréno, B & Kirkwood, JM 2008, 'Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion', Cancer, vol. 112, no. 5, pp. 982-994. https://doi.org/10.1002/cncr.23251
Hauschild, Axel ; Gogas, Helen ; Tarhini, Ahmad ; Middleton, Mark R. ; Testori, Alessandro ; Dréno, Brigitte ; Kirkwood, John M. / Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma : Expert opinion. In: Cancer. 2008 ; Vol. 112, No. 5. pp. 982-994.
@article{b242352b9e7348bca8bd36c0e55d7cda,
title = "Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion",
abstract = "Interferon-α-2b (IFNα2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from this agent. A review of the literature demonstrated little recent attention to supportive care in the management of IFN toxicities. An international group of experts with extensive personal experience in the use of IFNs worked together to develop practical guidelines for the use of IFNs. Practical recommendations were developed for patient education on the use of IFN; initial patient assessment and monitoring, including contraindications to the use of IFN, monitoring and managing adverse events, and IFN dose modification and discontinuation; IFN injection procedures; treatment of elderly patients; and use during pregnancy and nursing. Successful adjuvant therapy of melanoma with high-dose IFN requires close compliance with the treatment regimen. Recommendations for the recognition and management of adverse events are designed to enable more patients to complete the full planned course of treatment.",
keywords = "Adjuvant therapy, Adverse events, Interferon, Melanoma",
author = "Axel Hauschild and Helen Gogas and Ahmad Tarhini and Middleton, {Mark R.} and Alessandro Testori and Brigitte Dr{\'e}no and Kirkwood, {John M.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1002/cncr.23251",
language = "English",
volume = "112",
pages = "982--994",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma

T2 - Expert opinion

AU - Hauschild, Axel

AU - Gogas, Helen

AU - Tarhini, Ahmad

AU - Middleton, Mark R.

AU - Testori, Alessandro

AU - Dréno, Brigitte

AU - Kirkwood, John M.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Interferon-α-2b (IFNα2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from this agent. A review of the literature demonstrated little recent attention to supportive care in the management of IFN toxicities. An international group of experts with extensive personal experience in the use of IFNs worked together to develop practical guidelines for the use of IFNs. Practical recommendations were developed for patient education on the use of IFN; initial patient assessment and monitoring, including contraindications to the use of IFN, monitoring and managing adverse events, and IFN dose modification and discontinuation; IFN injection procedures; treatment of elderly patients; and use during pregnancy and nursing. Successful adjuvant therapy of melanoma with high-dose IFN requires close compliance with the treatment regimen. Recommendations for the recognition and management of adverse events are designed to enable more patients to complete the full planned course of treatment.

AB - Interferon-α-2b (IFNα2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from this agent. A review of the literature demonstrated little recent attention to supportive care in the management of IFN toxicities. An international group of experts with extensive personal experience in the use of IFNs worked together to develop practical guidelines for the use of IFNs. Practical recommendations were developed for patient education on the use of IFN; initial patient assessment and monitoring, including contraindications to the use of IFN, monitoring and managing adverse events, and IFN dose modification and discontinuation; IFN injection procedures; treatment of elderly patients; and use during pregnancy and nursing. Successful adjuvant therapy of melanoma with high-dose IFN requires close compliance with the treatment regimen. Recommendations for the recognition and management of adverse events are designed to enable more patients to complete the full planned course of treatment.

KW - Adjuvant therapy

KW - Adverse events

KW - Interferon

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=39749104201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749104201&partnerID=8YFLogxK

U2 - 10.1002/cncr.23251

DO - 10.1002/cncr.23251

M3 - Article

VL - 112

SP - 982

EP - 994

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -